File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/17474086.2016.1206465
- Scopus: eid_2-s2.0-84983770623
- WOS: WOS:000385558100006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Diagnosis and management of extranodal NK/T cell lymphoma nasal type
Title | Diagnosis and management of extranodal NK/T cell lymphoma nasal type |
---|---|
Authors | |
Keywords | Epstein Barr virus Extranodal NK/T-cell lymphoma hematopoietic stem cell transplantation L-asparaginase natural killer cell |
Issue Date | 2016 |
Citation | Expert Review of Hematology, 2016, v. 9, p. 861-871 How to Cite? |
Abstract | Abstract INTRODUCTION: Extranodal NK/T-cell lymphoma nasal type is a distinct clinicopathologic entity. The most common initial site of presentation is the nasopharyngeal area, but non-nasals sites including the skin and the gastrointestinal tract may be affected. AREAS COVERED: The diagnosis and management of NK/T-cell lymphoma is discussed, based on a literature search on PubMed. NK/T-cell lymphoma are typically positive for CD3 (cytoplasmic), CD56, cytotoxic markers (granzyme B, TIA1) and Epstein Barr virus (EBV). Plasma EBV DNA is an accurate surrogate biomarker for lymphoma load. For stage I/II nasal lymphoma, a combination of chemotherapy and radiotherapy yields the best results. Concomitant chemoradiotherapy and sequential chemotherapy and radiotherapy give similar response rates and survivals. For stage III/IV nasal lymphoma and non-nasal lymphomas, chemotherapy is the mainstay of treatment. Conventional anthracycline-based regimens are ineffective. Recommended chemotherapy protocols are based on the use of L-asparaginase combined with other effective drugs. Durable remission can be expected in at least 60% of patients irrespective of stage. Prognostically models based on clinicopathologic parameters and EBV DNA load are useful in stratification of patients for therapy. Expert commentary: Current treatment leads to long-term survival in a significant proportion of patients. For relapsed patients, novel strategies are needed. |
Persistent Identifier | http://hdl.handle.net/10722/232070 |
ISSN | 2023 Impact Factor: 2.3 2023 SCImago Journal Rankings: 0.699 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tse, EWC | - |
dc.contributor.author | Kwong, YL | - |
dc.date.accessioned | 2016-09-20T05:27:30Z | - |
dc.date.available | 2016-09-20T05:27:30Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Expert Review of Hematology, 2016, v. 9, p. 861-871 | - |
dc.identifier.issn | 1747-4086 | - |
dc.identifier.uri | http://hdl.handle.net/10722/232070 | - |
dc.description.abstract | Abstract INTRODUCTION: Extranodal NK/T-cell lymphoma nasal type is a distinct clinicopathologic entity. The most common initial site of presentation is the nasopharyngeal area, but non-nasals sites including the skin and the gastrointestinal tract may be affected. AREAS COVERED: The diagnosis and management of NK/T-cell lymphoma is discussed, based on a literature search on PubMed. NK/T-cell lymphoma are typically positive for CD3 (cytoplasmic), CD56, cytotoxic markers (granzyme B, TIA1) and Epstein Barr virus (EBV). Plasma EBV DNA is an accurate surrogate biomarker for lymphoma load. For stage I/II nasal lymphoma, a combination of chemotherapy and radiotherapy yields the best results. Concomitant chemoradiotherapy and sequential chemotherapy and radiotherapy give similar response rates and survivals. For stage III/IV nasal lymphoma and non-nasal lymphomas, chemotherapy is the mainstay of treatment. Conventional anthracycline-based regimens are ineffective. Recommended chemotherapy protocols are based on the use of L-asparaginase combined with other effective drugs. Durable remission can be expected in at least 60% of patients irrespective of stage. Prognostically models based on clinicopathologic parameters and EBV DNA load are useful in stratification of patients for therapy. Expert commentary: Current treatment leads to long-term survival in a significant proportion of patients. For relapsed patients, novel strategies are needed. | - |
dc.language | eng | - |
dc.relation.ispartof | Expert Review of Hematology | - |
dc.subject | Epstein Barr virus | - |
dc.subject | Extranodal NK/T-cell lymphoma | - |
dc.subject | hematopoietic stem cell transplantation | - |
dc.subject | L-asparaginase | - |
dc.subject | natural killer cell | - |
dc.title | Diagnosis and management of extranodal NK/T cell lymphoma nasal type | - |
dc.type | Article | - |
dc.identifier.email | Tse, EWC: ewctse@hku.hk | - |
dc.identifier.email | Kwong, YL: ylkwong@hkucc.hku.hk | - |
dc.identifier.authority | Tse, EWC=rp00471 | - |
dc.identifier.authority | Kwong, YL=rp00358 | - |
dc.identifier.doi | 10.1080/17474086.2016.1206465 | - |
dc.identifier.scopus | eid_2-s2.0-84983770623 | - |
dc.identifier.hkuros | 266589 | - |
dc.identifier.volume | 9 | - |
dc.identifier.spage | 861 | - |
dc.identifier.epage | 871 | - |
dc.identifier.eissn | 1747-4094 | - |
dc.identifier.isi | WOS:000385558100006 | - |
dc.identifier.issnl | 1747-4094 | - |